Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 29 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. CA 3043000

    DERIVES DE PROSTAGLANDINE LIBERANT DE L'OXYDE NITRIQUE POUR LE TRAITEMENT DU GLAUCOME A TENSION NORMALE

    BAUSCH & LOMB [US] · Granted May 17, 2018 · Expires May 12, 2038

    granted
  2. US 9969975

    Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

    Precision BioSciences, Inc. · Granted May 15, 2018 · Expires May 10, 2038

    granted
  3. US 9970006

    Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes

    Alnylam Pharmaceuticals, Inc. · Granted May 15, 2018 · Expires May 10, 2038

    granted
  4. US 9968693

    Small molecule imaging of fungi by positron emission tomography scanning

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 15, 2018 · Expires May 10, 2038

    granted
  5. US 9968664

    Fusion molecule based on novel TAA variant

    The Regents of the University of California · Granted May 15, 2018 · Expires May 10, 2038

    granted
  6. US 9963700

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Alnylam Pharmaceuticals, Inc. · Granted May 8, 2018 · Expires May 3, 2038

    granted
  7. US 9963699

    Methods for modulating C9ORF72 expression

    The Regents of the University of California · Granted May 8, 2018 · Expires May 3, 2038

    granted
  8. US 9963515

    Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted May 8, 2018 · Expires May 3, 2038

    granted
  9. US 9957292

    Compositions and methods for modulating angiopoietin-like 3 expression

    Ionis Pharmaceuticals, Inc. · Granted May 1, 2018 · Expires Apr 26, 2038

    granted
  10. US 9957507

    Compositions and methods for inhibiting expression of mutant EGFR gene

    Alnylam Pharmaceuticals, Inc. · Granted May 1, 2018 · Expires Apr 26, 2038

    granted
  11. US 9957504

    Compositions and methods for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted May 1, 2018 · Expires Apr 26, 2038

    granted
  12. US 9957501

    Nuclease-mediated regulation of gene expression

    Sangamo Therapeutics, Inc. · Granted May 1, 2018 · Expires Apr 26, 2038

    granted
  13. US 9957569

    Recurrent gene fusions in prostate cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted May 1, 2018 · Expires Apr 26, 2038

    granted
  14. US 9950011

    Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

    Precision BioSciences, Inc. · Granted Apr 24, 2018 · Expires Apr 19, 2038

    granted
  15. US 9950010

    Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

    Precision BioSciences, Inc. · Granted Apr 24, 2018 · Expires Apr 19, 2038

    granted
  16. US 9944926

    Induced exon inclusion in spinal muscle atrophy

    Sarepta Therapeutics, Inc. · Granted Apr 17, 2018 · Expires Apr 12, 2038

    granted
  17. US 9938531

    Compositions and methods for inhibiting expression of RRM2 genes

    Arrowhead Pharmaceuticals, Inc. · Granted Apr 10, 2018 · Expires Apr 5, 2038

    granted
  18. US 9938353

    Compositions, methods and uses for alpha-1 antitrypsin fusion molecules

    The Regents of the University of Colorado, a Body Corporate · Granted Apr 10, 2018 · Expires Apr 5, 2038

    granted
  19. US 9938344

    Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer

    PRECISION BIOLOGICS, INC. · Granted Apr 10, 2018 · Expires Apr 5, 2038

    granted
  20. US 9938582

    Recurrent gene fusions in prostate cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 10, 2018 · Expires Apr 5, 2038

    granted
  21. US 9932589

    EML4-ALK fusion gene

    CUREGENE K.K. · Granted Apr 3, 2018 · Expires Mar 29, 2038

    granted
  22. US 9932581

    Compositions and methods for modulating apolipoprotein C-III expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 3, 2018 · Expires Mar 29, 2038

    granted
  23. US 9932593

    Compositions and methods for inhibiting expression of CD274/PD-L1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Apr 3, 2018 · Expires Mar 29, 2038

    granted
  24. US 9932580

    Compositions and methods for modulating HBV expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 3, 2018 · Expires Mar 29, 2038

    granted